Lipoprotein(a) in clinical practice: A guide for the clinician

Chayakrit Krittanawong, Neil Sagar Maitra, Adham H. El-Sherbini, Nishant Shah, Carl J. Lavie, Michael D. Shapiro, Salim S. Virani

Research output: Contribution to journalReview articlepeer-review

4 Citations (Scopus)


Cardiovascular disease (CVD) remains the leading cause of death worldwide. Serum lipoprotein(a) (Lp(a)) has been shown to be an independent and causative risk factor for atherosclerotic CVD and calcific aortic valvular disease. Lp(a) continues to be studied, with emerging insights into the epidemiology of CVD with respect to Lp(a), pathogenic mechanisms of Lp(a) and strategies to mitigate disease. There have been novel insights into genetic polymorphisms of the LPA gene, interactions between concomitant risk factors and Lp(a) based on real-world data, and metabolic pathway targets for Lp(a) reduction. This review highlights these recent advances in our understanding of Lp(a) and discusses management strategies as recommended by cardiovascular professional societies, emerging therapies for lowering Lp(a), and future directions in targeting Lp(a) to reduce CVD.

Original languageEnglish
Pages (from-to)28-36
Number of pages9
JournalProgress in Cardiovascular Diseases
Publication statusPublished - 1 Jul 2023


  • Atherosclerosis
  • Calcific aortic stenosis
  • Coronary artery disease
  • Dyslipidemia
  • Genetics
  • Lipoprotein(a)
  • Pathophysiology
  • Risk factors


Dive into the research topics of 'Lipoprotein(a) in clinical practice: A guide for the clinician'. Together they form a unique fingerprint.

Cite this